Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

NCT06029127 2026-01-05

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02473133 2026-01-02

RTEP7

Phase 2 Completed

158 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04224337 2025-12-31

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Phase 2 Completed

16 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

43 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02314364 2025-12-16

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Phase 2 Completed

27 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05001347 2025-12-16

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2 Completed

25 enrolled 11 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05171777 2025-12-11

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

179 enrolled 33 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03836066 2025-12-04

TELMA

Phase 2 Completed

41 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04165083 2025-11-26

MK-3475-01B

Phase 2 Completed

102 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03132532 2025-11-25

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

20 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04644237 2025-11-21

DESTINY-LUNG02

Phase 2 Completed

152 enrolled 22 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01186861 2025-11-18

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Phase 2 Completed

205 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01221077 2025-11-18

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Phase 2 Completed

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02576431 2025-11-12

NAVIGATE

Phase 2 Completed

215 enrolled 5 FDA

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT03916419 2025-11-12